Sun R, Liu Y, Sun Y, Zhou M, Wang Y, Shi B
Acta Pharmacol Sin. 2024; 45(9):1937-1950.
PMID: 38750075
PMC: 11336244.
DOI: 10.1038/s41401-024-01287-8.
Xie M, Gong T, Wang Y, Li Z, Lu M, Luo Y
Int J Mol Sci. 2024; 25(8).
PMID: 38673726
PMC: 11050412.
DOI: 10.3390/ijms25084139.
Hoenigl M, Arastehfar A, Arendrup M, Bruggemann R, Carvalho A, Chiller T
Clin Microbiol Rev. 2024; 37(2):e0007423.
PMID: 38602408
PMC: 11237431.
DOI: 10.1128/cmr.00074-23.
Qu H, Li L, Chen H, Tang M, Cheng W, Lin T
J Control Release. 2023; 363:361-375.
PMID: 37751826
PMC: 11165424.
DOI: 10.1016/j.jconrel.2023.09.042.
Hu T, Huang Y, Liu J, Shen C, Wu F, He Z
Pharmaceutics. 2023; 15(7).
PMID: 37514008
PMC: 10383408.
DOI: 10.3390/pharmaceutics15071821.
Antifungal chemotherapies and immunotherapies for the future.
Armstrong-James D
Parasite Immunol. 2022; 45(2):e12960.
PMID: 36403106
PMC: 10078527.
DOI: 10.1111/pim.12960.
Cell membrane coated-nanoparticles for cancer immunotherapy.
Zeng Y, Li S, Zhang S, Wang L, Yuan H, Hu F
Acta Pharm Sin B. 2022; 12(8):3233-3254.
PMID: 35967284
PMC: 9366230.
DOI: 10.1016/j.apsb.2022.02.023.
The molecular regulation of autophagy in antimicrobial immunity.
Qin C, Lu Y, Bai L, Wang K
J Mol Cell Biol. 2022; 14(4).
PMID: 35278083
PMC: 9335221.
DOI: 10.1093/jmcb/mjac015.
Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis.
Lin X, He T, Tang R, Li Q, Wu N, Zhou Y
J Nanobiotechnology. 2022; 20(1):80.
PMID: 35168608
PMC: 8845357.
DOI: 10.1186/s12951-022-01287-y.
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.
Wu L, Seung E, Xu L, Rao E, Lord D, Wei R
Nat Cancer. 2022; 1(1):86-98.
PMID: 35121834
DOI: 10.1038/s43018-019-0004-z.
Cellular based immunotherapy for primary liver cancer.
Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L
J Exp Clin Cancer Res. 2021; 40(1):250.
PMID: 34372912
PMC: 8351445.
DOI: 10.1186/s13046-021-02030-5.
Ganoderma Lucidum Polysaccharides Enhance the Abscopal Effect of Photothermal Therapy in Hepatoma-Bearing Mice Through Immunomodulatory, Anti-Proliferative, Pro-Apoptotic and Anti-Angiogenic.
Xia Q, Lu C, Tong M, Yue M, Chen R, ZhuGe D
Front Pharmacol. 2021; 12:648708.
PMID: 34295244
PMC: 8290260.
DOI: 10.3389/fphar.2021.648708.
Structure-tuned membrane active Ir-complexed oligoarginine overcomes cancer cell drug resistance and triggers immune responses in mice.
Ji S, Yang X, Chen X, Li A, Yan D, Xu H
Chem Sci. 2021; 11(34):9126-9133.
PMID: 34094193
PMC: 8161536.
DOI: 10.1039/d0sc03975f.
Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies.
Mhaidly R, Verhoeyen E
Cancers (Basel). 2020; 12(7).
PMID: 32679920
PMC: 7409195.
DOI: 10.3390/cancers12071915.
Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells.
Liu B, Liu Z, Zhou M, Lin J, Chen X, Li Z
Mol Med Rep. 2019; 20(3):2823-2831.
PMID: 31524233
PMC: 6691195.
DOI: 10.3892/mmr.2019.10529.
NIR-Triggered Phototherapy and Immunotherapy via an Antigen-Capturing Nanoplatform for Metastatic Cancer Treatment.
Wang M, Song J, Zhou F, Hoover A, Murray C, Zhou B
Adv Sci (Weinh). 2019; 6(10):1802157.
PMID: 31131193
PMC: 6523374.
DOI: 10.1002/advs.201802157.
Roadmap and strategy for overcoming infusion reactions to nanomedicines.
Szebeni J, Simberg D, Gonzalez-Fernandez A, Barenholz Y, Dobrovolskaia M
Nat Nanotechnol. 2018; 13(12):1100-1108.
PMID: 30348955
PMC: 6320688.
DOI: 10.1038/s41565-018-0273-1.
Impact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer.
DCruz O, Qazi S, Hwang L, Ng K, Trieu V
Onco Targets Ther. 2018; 11:2779-2796.
PMID: 29785126
PMC: 5957068.
DOI: 10.2147/OTT.S161905.
Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Sau S, Alsaab H, Bhise K, Alzhrani R, Nabil G, Iyer A
J Control Release. 2018; 274:24-34.
PMID: 29391232
PMC: 5847475.
DOI: 10.1016/j.jconrel.2018.01.028.
BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.
Dorrie J, Babalija L, Hoyer S, Gerer K, Schuler G, Heinzerling L
Int J Mol Sci. 2018; 19(1).
PMID: 29346301
PMC: 5796234.
DOI: 10.3390/ijms19010289.
